Servier

Servier is a laboratory governed by a foundation that invests over 20% of its revenue from brand-name medicines in research and development in oncology, neuroscience, immuno-inflammation, cardiovascular diseases and metabolism. In 2022, the company recorded a turnover of 4.9 billion euros. Servier capitalizes on the talent and engagement of the 21,400 people employed in over 150 countries. In June 2023, nearly 1,500 employees in Research and Development will be regrouped in a new R&D Institute at Paris-Saclay.

Servier focuses its research and development efforts in Neuroscience on developing new medicines that slow the progression of rare diseases or diseases with a genetic origin. Servier has developed an ASO screening platform now available, allowing first the selection of the most promising ASO using Servier’s own algorithm and then the evaluation of their potency and safety using different in vitro cellular screening assays (cell lines, primary neuronal cultures, patients neurons derived from iPSCs…) and in vivo evaluations in rodents and Non-Human Primates. Finally, as a pharmaceutical company, Servier has a wide expertise in preclinical and clinical trials together with biomarkers assay development (from the assay development to its validation for clinical use) .For all these reasons, Servier being a partner of the RHU INNOV-4ePiK is in perfect coherence with their respective and converging ambition towards improving the diagnosis and prognosis of K-DEE, to better understand and model the pathology, to identify innovative and useful clinical biomarkers, to develop pertinent preclinical models, as well as new innovative and authority-approved clinical protocols including “virtual control” arm. Servier participates in the EBISC2 Innovative Medicines Initiative (IMI) that aims to provide access to a broad biobank of well-characterized and quality controlled iPSCs from diverse diseases and genetic backgrounds along with comprehensive datasets to the academic and industrial scientific communities worldwide.